Literature DB >> 27669967

Therapeutic Antibodies by Phage Display.

Hyunbo Shim1.   

Abstract

BACKGROUND: Antibody phage display is a major technological platform for the generation of fully human antibodies for therapeutic purposes. The in vitro binder selection by phage display allows researchers to have more extensive control over binding parameters and facilitates the isolation of clinical candidate antibodies with desired binding and/or functional profiles.
METHODS: Since the invention of antibody phage display in late 1980s, significant technological advancements in the design, construction, and selection of the antibody libraries have been made, and several fully human antibodies generated by phage display are currently approved or in various clinical development stages.
RESULTS: In this review, the background and details of antibody phage display technology, and representative antibody libraries with natural or synthetic sequence diversity and different construction strategies are described. The generation, optimization, functional and biophysical properties, and preclinical and clinical developments of some of the phage display-derived therapeutic antibodies approved for use in patients or in late-stage clinical trials are also discussed.
CONCLUSION: With evolving novel disease targets and therapeutic strategies, antibody phage display is expected to continue to play a central role in the development of the next generation of therapeutic antibodies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Phage display; antibodies; antibody libraries; fully human antibodies; natural antibody libraries; semi-synthetic antibody libraries.; syntheticzzm321990antibody libraries; therapeutic antibodies

Mesh:

Substances:

Year:  2016        PMID: 27669967     DOI: 10.2174/1381612822666160923113714

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  9 in total

1.  Generating FN3-Based Affinity Reagents Through Phage Display.

Authors:  Kevin Gorman; Jennifer McGinnis; Brian Kay
Journal:  Curr Protoc Chem Biol       Date:  2018-06-07

2.  A Novel Synthetic Antibody Library with Complementarity-Determining Region Diversities Designed for an Improved Amplification Profile.

Authors:  Xuelian Bai; Moonseon Jang; Nam Ju Lee; Thi Thu Ha Nguyen; Mooyoung Jung; Jeong Yeon Hwang; Hyunbo Shim
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 3.  Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.

Authors:  Nneka Pu Korie; Kwesi Z Tandoh; Samuel K Kwofie; Osbourne Quaye
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-17

Review 4.  Advances in the Isolation of Specific Monoclonal Rabbit Antibodies.

Authors:  Zaibao Zhang; Huijuan Liu; Qian Guan; Lei Wang; Hongyu Yuan
Journal:  Front Immunol       Date:  2017-05-05       Impact factor: 7.561

5.  Next-generation sequencing enables the discovery of more diverse positive clones from a phage-displayed antibody library.

Authors:  Wonjun Yang; Aerin Yoon; Sanghoon Lee; Soohyun Kim; Jungwon Han; Junho Chung
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

Review 6.  Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

Authors:  Noel Jacques Awi; Sin-Yeang Teow
Journal:  J Pathog       Date:  2018-06-03

7.  Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.

Authors:  Agathe Dubuisson; Cécile Favreau; Eric Fourmaux; Sabrina Lareure; Rafael Rodrigues-Saraiva; Catherine Pellat-Deceunynck; Said El Alaoui; Olivier Micheau
Journal:  Cell Death Dis       Date:  2019-02-04       Impact factor: 8.469

Review 8.  Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers.

Authors:  Kyusang Hwang; Jin Hwan Yoon; Ji Hyun Lee; Sukmook Lee
Journal:  Biomedicines       Date:  2021-01-05

Review 9.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.